These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 2430569)

  • 1. Impaired cAMP metabolism associated with abnormal function of thrombopathic canine platelets.
    Boudreaux MK; Dodds WJ; Slauson DO; Catalfamo JL
    Biochem Biophys Res Commun; 1986 Oct; 140(2):595-601. PubMed ID: 2430569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence for regulatory control of canine platelet phosphodiesterase.
    Boudreaux MK; Dodds WJ; Slauson DO; Catalfamo JL
    Biochem Biophys Res Commun; 1986 Oct; 140(2):589-94. PubMed ID: 3022725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of activation of protein kinase C on the agonist-induced stimulation and inhibition of cyclic AMP formation in intact human platelets.
    Williams KA; Murphy W; Haslam RJ
    Biochem J; 1987 May; 243(3):667-78. PubMed ID: 2444206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VIP elevates platelet cyclic AMP (cAMP) levels and inhibits in vitro platelet activation induced by platelet-activating factor (PAF).
    Cox CP; Linden J; Said SI
    Peptides; 1984; 5(2):325-8. PubMed ID: 6206481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potentiation of antiaggregating activity of adenosine by a phosphodiesterase inhibitor, EG626 (oxagrelate), in human platelets in vitro.
    Azuma H; Takashima Y; Ishikawa M; Yamakado T
    Jpn J Pharmacol; 1984 Feb; 34(2):159-70. PubMed ID: 6205194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition by forskolin of cytosolic calcium rise, shape change and aggregation in quin2-loaded human platelets.
    Sage SO; Rink TJ
    FEBS Lett; 1985 Aug; 188(1):135-40. PubMed ID: 2410292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of forskolin and organic nitrate on aggregation and intracellular cyclic nucleotide content in human platelets.
    Anfossi G; Massucco P; Mularoni E; Cavalot F; Mattiello L; Trovati M
    Gen Pharmacol; 1994 Oct; 25(6):1093-100. PubMed ID: 7875530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of cyclic GMP-binding and cyclic AMP-specific phosphodiesterases of rat platelets by a mechanism involving cyclic AMP-dependent phosphorylation.
    Tremblay J; Lachance B; Hamet P
    J Cyclic Nucleotide Protein Phosphor Res; 1985; 10(4):397-411. PubMed ID: 2411769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the cAMP-elevating agents cilostamide, cilostazol and forskolin on the phosphorylation of Akt and GSK-3beta in platelets.
    Hayashi H; Sudo T
    Thromb Haemost; 2009 Aug; 102(2):327-35. PubMed ID: 19652884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of forskolin on platelet deaggregation and cyclic AMP generation.
    Kariya T; Morito F; Sakai T; Takahata K; Yamanaka M
    Naunyn Schmiedebergs Arch Pharmacol; 1985 Oct; 331(1):119-21. PubMed ID: 2999615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Agents that elevate platelet cAMP stimulate the formation of phosphatidylinositol 4-phosphate in intact human platelets.
    de Chaffoy de Courcelles D; Roevens P; van Belle H
    FEBS Lett; 1986 Jan; 195(1-2):115-8. PubMed ID: 2417883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of protease-activated receptor (PAR) 1 and PAR4 signaling in human platelets by compartmentalized cyclic nucleotide actions.
    Bilodeau ML; Hamm HE
    J Pharmacol Exp Ther; 2007 Aug; 322(2):778-88. PubMed ID: 17525299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevation of cyclic AMP decreases phosphoinositide turnover and inhibits thrombin-induced secretion in human platelets.
    Ryningen A; Olav Jensen B; Holmsen H
    Biochim Biophys Acta; 1998 Nov; 1394(2-3):235-48. PubMed ID: 9795233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preliminary studies of a platelet function disorder in Simmental cattle.
    Searcy GP; Sheridan D; Dobson KA
    Can J Vet Res; 1990 Jun; 54(3):394-6. PubMed ID: 2379119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Octimibate, a potent non-prostanoid inhibitor of platelet aggregation, acts via the prostacyclin receptor.
    Merritt JE; Hallam TJ; Brown AM; Boyfield I; Cooper DG; Hickey DM; Jaxa-Chamiec AA; Kaumann AJ; Keen M; Kelly E
    Br J Pharmacol; 1991 Jan; 102(1):251-9. PubMed ID: 1710526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interrelation of prostaglandin endoperoxide (prostaglandin G2) and cyclic 3',5'-adenosine monophosphate in human blood platelets.
    Salzman EW
    Biochim Biophys Acta; 1977 Aug; 499(1):48-60. PubMed ID: 196670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The lack of correlation between inhibition of aggregation and cAMP levels with canine platelets.
    Tsien WH; Sass SP; Sheppard H
    Thromb Res; 1982 Nov; 28(4):509-19. PubMed ID: 6187084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defective platelet-fibrinogen interaction in hereditary canine thrombopathia.
    Catalfamo JL; Raymond SL; White JG; Dodds WJ
    Blood; 1986 Jun; 67(6):1568-77. PubMed ID: 3011147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in the mode of action of 1-oleoyl-2-acetyl-glycerol and phorbol ester in platelet activation.
    Ashby B; Kowalska MA; Wernick E; Rigmaiden M; Daniel JL; Smith JB
    J Cyclic Nucleotide Protein Phosphor Res; 1985; 10(5):473-83. PubMed ID: 2999204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Intracellular actions of antiplatelet drugs which affect cyclic AMP metabolism in platelets--their effects on Ca2+ mobilization and protein phosphorylation in human platelets].
    Nishikawa M; Saitoh M; Deguchi K; Shirakawa S
    Rinsho Byori; 1990 Jul; Suppl 86():54-61. PubMed ID: 2172597
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.